NCT02489500View on ClinicalTrials.gov

Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib

PHASE3TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

April 28, 2017

Study Completion Date

April 28, 2017

Conditions
AL Amyloidosis
Interventions
DRUG

Bortezomib

"Conditioning Regimen:~Drug: Bortezomib: 1.0 mg/m2/dose D -6, D -3, D +1, D + 4 Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1"

DRUG

Melphalan

"Conditioning Regimen:~Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1 Stem Cell Transplant: D 0"

DRUG

Neupogen

granulocyte colony-stimulating factor (G-CSF) mobilization 16mcg/kg x 4 days

PROCEDURE

Stem Cell Collection

collect at least 2.5 million cluster of differentiation 34 (CD34)+ stem cells

PROCEDURE

Stem cell infusion

infusion of previously collected autologous stem cells

Trial Locations (1)

02118

Boston Medical Center, Boston

Sponsors
All Listed Sponsors
lead

Boston Medical Center

OTHER

NCT02489500 - Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib | Biotech Hunter | Biotech Hunter